MarketPulse

net loss

54 articles
BenzingaBenzinga··Globe Newswire

Advanced Flower Capital Posts $20.7M Full-Year Loss Despite Q4 Profitability

$AFCG reported Q4 2025 profit but full-year loss of $20.7M. Company declared Q1 2026 dividend while executing BDC conversion strategy.
AFCGfinancial resultsnet loss
The Motley FoolThe Motley Fool··Eric Volkman

Calumet Shares Decline 11% After Missing Earnings Expectations Despite Revenue Beat

Calumet's stock fell 11% after missing earnings expectations with a $0.43 loss per share versus forecasted $0.22, despite beating revenue guidance at $1.04 billion.
CLMTstock declineearnings miss
GlobeNewswire Inc.GlobeNewswire Inc.··Holzer & Holzer, Llc

Holzer & Holzer Launches Investigation Into Eos Energy Following $969.6M Loss

Holzer & Holzer investigates Eos Energy after $969.6M loss disclosure. Firm examines whether investors received adequate financial disclosures.
CRWVCWHEOSEclass action lawsuitsecurities investigation
GlobeNewswire Inc.GlobeNewswire Inc.··Holzer & Holzer, Llc

Law Firm Launches Securities Probe Into Camping World's $105.6M Loss and Dividend Halt

Law firm investigates Camping World for potential securities violations following $105.6M loss and dividend suspension that sparked stock decline.
CWHsecurities investigationnet loss
BenzingaBenzinga··Business Wire

Legal Inquiry Launched Into Camping World Following Consecutive Stock Declines

Law firm investigates Camping World for potential securities fraud following consecutive stock declines tied to downward guidance revisions and reported losses.
CWHstock declineguidance reduction
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Perimeter Solutions Posts 16% Revenue Growth Despite Widened 2025 Net Loss

Perimeter Solutions grew revenue 16% to $653M in 2025, but net loss widened to $206M due to $435M in founders advisory fees.
PRMacquisitionnet loss
The Motley FoolThe Motley Fool··Robert Izquierdo

Lumen Director Sells 45,000 Shares as Telecom Giant Battles Revenue Decline

Lumen director sells 45,000 shares amid telecom revenue decline. Company reported $12.4B revenue in 2025, down from prior year, while carrying $17B debt.
LUMNvaluationdebt burden
The Motley FoolThe Motley Fool··Daniel Miller

Ford Posts $11.1B Loss as Tariffs and Supply Chain Disruptions Derail Q4

Ford reports $11.1B Q4 loss due to $900M tariff costs and aluminum supply disruptions, though revenue beat expectations. Company projects 2026 recovery.
FFpBFpCFpDnet loss2026 outlook
The Motley FoolThe Motley Fool··Adé Hennis

Redwire Director Liquidates $51.5M in Stock Amid Financial Headwinds

Redwire director liquidates $51.5M in stock over two weeks as company faces doubled net losses and volatile trading conditions.
RDWaerospace and defensenet loss
The Motley FoolThe Motley Fool··Scott Levine

Trilogy Metals Shares Plummet Amid Full-Year Loss and Major Investor Exit

Trilogy Metals shares tumbled after reporting a $42.2 million full-year loss and major investor Paulson & Co. exiting its position entirely.
TMQstock declineQ4 2025 earnings
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Daily Journal Posts Q1 Revenue Gains Despite Investment Losses

Daily Journal's Q1 revenue grew 10% to $19.5M, but a $8M net loss resulted from $11.7M in investment portfolio losses, offsetting operational gains.
DJCOnet lossrevenue growth
The Motley FoolThe Motley Fool··Adé Hennis

Snap CTO Divests $10.6M in Shares as Stock Hits Historic Low

Snap's CTO sold $10.6M in shares as stock hits all-time low of $4.72, amid weak revenue guidance and continued losses in competitive ad market.
METASNAPstock declinenet loss
The Motley FoolThe Motley Fool··Neha Chamaria

Cleveland-Cliffs Shares Tumble 32.5% on Substantial 2025 Loss Amid Sector Headwinds

Cleveland-Cliffs shares plunged 32.5% after reporting $1.4 billion loss in 2025, hit by weak auto demand and unprofitable steel deal. Management expects 2026 recovery.
CLFMTearnings missnet loss
BenzingaBenzinga··Prnewswire

Citius Oncology Posts Maiden Revenue of $3.9M From LYMPHIR Launch

Citius Oncology reports maiden revenue of $3.9M from LYMPHIR immunotherapy launch in December 2025, marking transition to commercial-stage biopharmaceutical company.
CTXRCTORnet lossFDA approval